Czechia· CZ-0238760
RINVOQ
A upadacitinib product containing upadacitinib hemihydrate, registered in Czechia by AbbVie Deutschland GmbH & Co.KG, Ludwigshafen. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Upadacitinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AF03 (upadacitinib), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Upadacitinib · ATC L04AF03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of upadacitinib costs, country by country.
Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Upadacitinib · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$32.01
The record
At a glance
SÚKL (Czech Republic)- Active substance
- UPADACITINIB HEMIHYDRATE
- Manufacturer
- AbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- Country
- Czechia (CZ)
- ATC code
- L04AF03
- ATC class
- Upadacitinib
- Defined daily dose
- 15 mg, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl023876098(2X49) KALCZK 55480.22
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
407 interactions on record for upadacitinib.
Graded by severity as the source publishes them — 337 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Upadacitinib · interactions on record
407 records
- 337 severe
- 63 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Upadacitinib in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf4e4699-4107-4db3-8f0a-a6b47ca53838 GET /v1/drugs/cf4e4699-4107-4db3-8f0a-a6b47ca53838?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL PRO",
"source": "sukl",
"strength": "15MG",
"pack_size": "98(2X49) KAL",
"substance": "UPADACITINIB HEMIHYDRATE",
"cz_kod_sukl": "0238760",
"product_type": "CH",
"substance_codes": "18040",
"registration_state": "R",
"registration_number": "EU/1/19/1404/005"
}See everything about upadacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.